Results.
Of the 617 samples that were analyzed, 73 (11.8%) were found to carry pathogenic GGGGCC repeat expansions in C9ORF72 (table 1 and table e-1 on the Neurology ® Web site at www.neurology.org). Interestingly, a significantly higher mutation frequency was observed within the FTD-ALS patient group (9/20; 45.0%), compared to the group of patients with pure ALS (64/568; 11.3%) ( p ϭ 0.0002). Among familial cases (fALS), 37.1% (49/132) showed a repeat expansion, while 4.9% (24/485) of the sporadic cases (sALS) were positive. In the remainder of our patient series, repeat-units ranged from 2 to 28, which we considered normal in this study.
Average age at onset for expansion carriers was 56.8 Ϯ 8.0 years (range 39 -80) and males accounted for 53.4% (n ϭ 39). Ethnicities of positive cases were white (n ϭ 72; 98.6%) and African American (n ϭ 1; 1.4%). The mutation cases with known site of onset were equally distributed among bulbar, limb-upper, and limb-lower for the pure ALS cases (20/20/23 respectively, 1 unknown), whereas the FTD-ALS cases presented with bulbar, limb-upper, or generalized onset (4/4/1, respectively). Overall, bulbar presentation was somewhat more common in C9ORF72 mutation carriers (24/73; 32.9%) compared to non-C9ORF72 mutation carriers (107/544; 19.7%) ( p ϭ 0.014).
Discussion. The frequency of repeat expansion carriers in fALS (37.1%) reported in this study was highly similar to that previously reported in a selected series of European patients with ALS (38.1%) and slightly higher than our published mutation frequency from a US fALS series (23.5%). This may be due to the ALS cases in our previous publication being collected at 1 location (Mayo Clinic Florida), primarily from incident patients, whereas Coriell samples were collected at multiple centers throughout the United States. The frequency of repeat expansion carriers in sALS (4.9%) in this study was highly comparable to our previously reported frequency of 4.1%.
Only limited clinical features of C9ORF72 mutation carriers have thus far been described. [2] [3] [4] [5] Clinical data available on the patients we studied indicate considerable clinical heterogeneity among mutation carriers with onset ages ranging from 39 to 80 years, with limb, bulbar, and generalized presentations at disease onset. All mutation carriers presented with upper and lower motor neuron features, with the highest mutation frequency among FTD-ALS patients. Although most mutation carriers were white, we also report the first African American patient with a C9ORF72 repeat expansion.
In our study a characteristic stutter amplification pattern by repeat-primed PCR was considered evidence for pathogenicity; however, future Southern blot analyses will be required to determine the mutant allele length in each individual patient. Future studies should also clarify the minimal length of a pathogenic repeat expansion.
The reporting of C9ORF72 mutation status of this large cohort of patients with ALS from the Coriell Institute provides an essential resource for the scientific community. Acquisition of available lymphoblast cell lines derived from this cohort of mutated patients will allow accurate repeat sizing, genotype-phenotype correlations, and a source of mutant cells for in vitro studies.
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